The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
Open accessAbstract
It has previously been shown that bone marrow-generated dendritic cells (DC) are potent stimulators in allogeneic mixed leukocyte reactions and are capable of activating naive CD4+ T cells in situ in an antigen-specific manner. In this study we have investigated whether bone marrow-generated DC are capable of inducing antigen-specific CD8+ T cell responses in vivo. Initial attempts to induce specific cytotoxic T lymphocyte (CTL) responses in mice injected with bone marrow-generated DC pulsed with ovalbumin (OVA) peptide were frustrated by the presence of high levels of nonspecific lytic activity, which obscured, though not completely, the presence of Ag-specific CTL. Using conditions that effectively differentiate between antigen-specific and nonspecific lytic activity, we have shown that bone marrow-generated DC pulsed with OVA peptide are potent inducers of OVA-specific CTL responses in vivo, compared with splenocytes or RMA-S cells pulsed with OVA peptide, or compared with immunization with free OVA peptide mixed with adjuvant. Antibody-mediated depletion experiments have shown that the cytotoxic effector cells consist primarily of CD8+ cells, and that induction of CTL in vivo is dependent on CD4+ as well as on CD8+ T cells. These results provide the basis for exploring the role of bone marrow-generated DC in major histocompatibility class I-restricted immune responses, and they provide the rationale for using bone marrow-generated DC in CTL-mediated immunotherapy of cancer and infectious diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,658
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
Introduction of soluble protein into the class I pathway of antigen processing and presentation
Moore, M. W., Carbone, F. R., & Bevan, M. J. (1988) · Cell · doi:10.1016/s0092-8674(88)91043-4 · Cited by 1,092
Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice.
Steinman, R. M., & Witmer, M. D. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.10.5132 · Cited by 818
Inaba, K., Metlay, J. P., Crowley, M. T., & Steinman, R. M. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.2.631 · Cited by 657
Helper activity is required for the in vivo generation of cytotoxic T lymphocytes
Keene, J.-A., & Forman, J. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.3.768 · Cited by 500
Inaba, K., Inaba, M., Naito, M., & Steinman, R. M. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.479 · Cited by 473
Exact prediction of a natural T cell epitope
Rötzschke, O., Falk, K., Stevanovic, S., Jung, G., Walden, P., & Rammensee, H. (1991) · European Journal of Immunology · doi:10.1002/eji.1830211136 · Cited by 446
Liu, L. M., & MacPherson, G. G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.5.1299 · Cited by 284
Macatonia, S. E., Taylor, P. M., Knight, S. C., & Askonas, B. A. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.4.1255 · Cited by 258
Cited by
Immunobiology of Dendritic Cells
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,634
Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
Boczkowski, D., Nair, S. K., Snyder, D., & Gilboa, E. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.465 · Cited by 915
Self-citationZitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., & Storkus, W. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.87 · Cited by 828
DNA–based immunization by in vivo transfection of dendritic cells
Condon, C., Watkins, S. C., Celluzzi, C. M., Thompson, K., & Falo, L. D. (1996) · Nature Medicine · doi:10.1038/nm1096-1122 · Cited by 819
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.
Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., & Falo, L. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.283 · Cited by 717
Bender, A., Sapp, M., Schuler, G., Steinman, R. M., & Bhardwaj, N. (1996) · Journal of Immunological Methods · doi:10.1016/0022-1759(96)00079-8 · Cited by 663
Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
Gong, J., Chen, D., Kashiwaba, M., & Kufe, D. (1997) · Nature Medicine · doi:10.1038/nm0597-558 · Cited by 591
Dendritic cells in the T‐cell areas of lymphoid organs
Steinman, R. M., Pack, M., & Inaba, K. (1997) · Immunological Reviews · doi:10.1111/j.1600-065x.1997.tb00956.x · Cited by 556
Brossart, P., Wirths, S., Stuhler, G., Reichardt, V. L., Kanz, L., & Brugger, W. (2000) · Blood · doi:10.1182/blood.v96.9.3102 · Cited by 552
Dendritic Cell Vaccines for Cancer Immunotherapy
Timmerman, M., & Levy, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.507 · Cited by 485
Ashley, D. M., Faiola, B., Nair, S., Hale, L. P., Bigner, D. D., & Gilboa, E. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1177 · Cited by 439
Self-citationNair, S. K., Boczkowski, D., Morse, M., Cumming, R. I., Lyerly, H. K., & Gilboa, E. (1998) · Nature Biotechnology · doi:10.1038/nbt0498-364 · Cited by 398
Self-citationSpinning molecular immunology into successful immunotherapy
Pardoll, D. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri774 · Cited by 360
A potential role of macrophage activation in the treatment of cancer
Klimp, A. H., de Vries, E. G. E., Scherphof, G. L., & Daemen, T. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00203-7 · Cited by 360
Norbury, C. C., Chambers, B. J., Prescott, A. R., Ljunggren, H., & Watts, C. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270141 · Cited by 350
Brossart, P., Heinrich, K. S., Stuhler, G., Behnke, L., Reichardt, V. L., Stevanovic, S., Muhm, A., Rammensee, H.-G., Kanz, L., & Brugger, W. (1999) · Blood · doi:10.1182/blood.v93.12.4309 · Cited by 306
Kim, G.-Y., Kim, K.-H., Lee, S.-H., Yoon, M.-S., Lee, H.-J., Moon, D.-O., Lee, C.-M., Ahn, S.-C., Park, Y. C., & Park, Y.-M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.8116 · Cited by 306
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
Saxena, M., & Bhardwaj, N. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.007 · Cited by 305
Tumor-infiltrating T lymphocytes: Friends or foes?
Yu, P., & Fu, Y.-X. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700389 · Cited by 299
Immature myeloid cells and cancer-associated immune suppression
Kusmartsev, S., & Gabrilovich, D. I. (2002) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-002-0280-8 · Cited by 297
Choudhury, A., Gajewski, J. L., Liang, J. C., Popat, U., Claxton, D. F., Kliche, K.-O., Andreeff, M., & Champlin, R. E. (1997) · Blood · doi:10.1182/blood.v89.4.1133 · Cited by 285
Berard, F., Blanco, P., Davoust, J., Neidhart-Berard, E.-M., Nouri-Shirazi, M., Taquet, N., Rimoldi, D., Cerottini, J. C., Banchereau, J., & Palucka, A. K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.11.1535 · Cited by 284
Bell, D., Young, J. W., & Banchereau, J. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60023-1 · Cited by 277
Young, J. W., & Inaba, K. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.7 · Cited by 269
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
Sánchez-Paulete, A. R., Teijeira, A., Cueto, F. J., Garasa, S., Pérez-Gracia, J. L., Sánchez-Arráez, A., Sancho, D., & Melero, I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx237 · Cited by 267
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
Mayordomo, J. I., Loftus, D. J., Sakamoto, H., De Cesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., & DeLeo, A. B. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1357 · Cited by 253
Tumors and inflammatory infiltrates: Friends or foes?
Brigati, C., Noonan, D. M., Albini, A., & Benelli, R. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1015587423262 · Cited by 230
“Also, dendritic cell-based vaccines have been constructed by pulsing them with tumor peptides in attempts to elicit a strong and specific T-cell response in mouse models [84].”
Caruso, D. A., Orme, L. M., Neale, A. M., Radcliff, F. J., Amor, G. M., Maixner, W., Downie, P., Hassall, T. E., Tang, M. L. K., & Ashley, D. M. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000668 · Cited by 165
“Four out of 7 patients showed induction of T cell cytotoxicity, while 2 of 4 patients who were subjected to additional surgery demonstrated cytotoxic and memory T-cell tumor infiltration (Porgador and Gilboa, 1995).”
BackgroundQuercetin protects against atherosclerosis by inhibiting dendritic cell activation
Lin, W., Wang, W., Wang, D., & Ling, W. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700031 · Cited by 77
Metadata
- Authors
- Porgador, A., & Gilboa, E.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1995-07-01
- Volume
- 182
- Issue
- 1
- Pages
- 255-260
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2106934028
- Cited by
- 362
- References
- 21
- FWCI
- 11.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.